Shree Ganesh Biotech Reports Q1 FY27 Net Loss Amidst Rising Costs

Net Loss: ₹0.57 crore
Revenue from Operations: ₹1.43 crore

Reader Takeaway: Rising material costs drove a Q1 net loss, despite slight revenue growth.

What just happened

Shree Ganesh Biotech (India) Ltd has reported a net loss of ₹0.57 crore for the quarter ended June 30, 2026. This marks a significant shift from the same period last year, when the company posted a net profit of ₹0.33 crore. Revenue from operations saw a marginal increase to ₹1.43 crore from ₹1.38 crore in the corresponding quarter of the previous year.

Why this matters

The swing from profit to loss is a key concern for shareholders. It indicates potential operational challenges and margin pressures. The increase in total expenses to ₹2.32 crore from ₹1.47 crore in the prior year, driven mainly by a sharp rise in the cost of materials consumed to ₹1.87 crore, directly impacted the company's bottom line.

The backstory

In the previous year's quarter, Shree Ganesh Biotech had managed to report a profit of ₹0.33 crore with total expenses at ₹1.47 crore. This quarter, while revenue saw a modest rise, expenses surged by nearly 58%, overwhelming the top-line growth and resulting in a net loss.

What changes now

The company's profitability has been directly affected. Investors will be watching closely to see if management can implement cost-control measures, especially concerning material costs, to steer the company back to profitability. The basic Earnings Per Share (EPS) has also moved to a negative (₹0.01) from a positive ₹0.01 in the year-ago period.

Risks to watch

The primary risk highlighted is the escalating cost of materials consumed, which is eroding profitability. Additionally, the company has noted that a tax provision will be made at year-end, meaning the final annual earnings could be further impacted by actual tax liabilities.

Peer comparison

As Shree Ganesh Biotech operates in a single business segment, a direct peer comparison based on segment results is not applicable from this filing. However, the general trend in the biotechnology sector often involves significant R&D and raw material costs, making margin management crucial for all players.

Context metrics (time-bound)

For the quarter ended June 30, 2026, Revenue from Operations stood at ₹1.43 crore, compared to ₹1.38 crore for the quarter ended June 30, 2025. Total expenses rose to ₹2.32 crore from ₹1.47 crore year-on-year.

What to track next

Investors should monitor future quarterly results for evidence of expense management, particularly in the cost of materials. The company's ability to improve its profit margins and return to consistent profitability will be key factors to watch.